Lumavita AG is a specialty biopharmaceutical company dedicated to developing innovative anti-infectives for women’s health. Based in Basel, Switzerland, Lumavita has two projects entering clinical development in the coming months.

Development Portfolio

Lumavita’s portfolio consists of two anti-infective compounds: LMV-601 and LMV-602. LMV-601, a first-in-class PC-PLC inhibitor, is in Phase I clinical development for the potential treatment of Human Papillomavirus infections of the cervix. First pre-clinical data also indicate activity against Herpes Simplex Virus. LMV-601 was discovered at DKFZ, Germany’s renowned Cancer Research Centre.

LMV-602, a macrolide antibiotic, is currently in re-formulation development and will enter into clinics beginning 2011 for the indication of vaginitis.